Holen Sie sich die Stockscreener-App
3.90
2.50%
-0.10
Handel nachbörslich:
4.00
0.10
+2.56%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CTSO?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$4.00
Offen:
$4.13
24-Stunden-Volumen:
13,674
Relative Volume:
1.17
Marktkapitalisierung:
$12.29M
Einnahmen:
$37.20M
Nettoeinkommen (Verlust:
$-11.85M
KGV:
-20.44
EPS:
-0.1908
Netto-Cashflow:
$-10.59M
1W Leistung:
-20.57%
1M Leistung:
-42.82%
6M Leistung:
-65.57%
1J Leistung:
-79.12%
1-Tages-Spanne:
$3.765
$4.15
1-Wochen-Bereich:
$3.765
$5.20
52-Wochen-Spanne:
$3.765
$20.40
Cytosorbents Corp Stock (CTSO) Company Profile
Firmenname
Cytosorbents Corp
Sektor
Branche
Telefon
973-329-8885
Adresse
305 COLLEGE ROAD EAST, PRINCETON, NJ
Compare CTSO vs ABT, MDT, SYK, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CTSO
Cytosorbents Corp
|
3.90 | 13.80M | 37.20M | -11.85M | -10.59M | -0.1908 |
ABT
Abbott Laboratories
|
98.83 | 175.27B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
86.29 | 113.38B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
275.39 | 104.47B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
43.65 | 63.65B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.32 | 49.74B | 6.30B | 1.07B | 1.09B | 1.8406 |
Cytosorbents Corp Stock (CTSO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-09-07 | Eingeleitet | B. Riley Securities | Buy |
| 2021-10-14 | Fortgesetzt | B. Riley Securities | Buy |
| 2020-09-17 | Eingeleitet | Jefferies | Buy |
| 2020-09-01 | Eingeleitet | SVB Leerink | Outperform |
| 2017-08-08 | Bestätigt | Maxim Group | Buy |
| 2016-10-26 | Eingeleitet | Aegis Capital | Buy |
| 2016-05-24 | Eingeleitet | Maxim Group | Buy |
| 2015-10-29 | Hochstufung | WBB Securities | Speculative Buy → Buy |
| 2015-05-12 | Bestätigt | MLV & Co | Buy |
| 2015-04-01 | Bestätigt | MLV & Co | Buy |
| 2015-03-05 | Eingeleitet | MLV & Co | Buy |
| 2015-02-25 | Eingeleitet | WBB Securities | Speculative Buy |
| 2015-01-27 | Bestätigt | H.C. Wainwright | Buy |
Alle ansehen
Cytosorbents Corp Aktie (CTSO) Neueste Nachrichten
Cytosorbents Corporation (CTSO) stock price, news, quote and history - Yahoo Finance UK
CytoSorbents regains Nasdaq $1.00 minimum bid compliance; MVLS shortfall remains under review - TradingView
Nasdaq keeps CytoSorbents (NASDAQ: CTSO) on watch after $1 bid price return - Stock Titan
CytoSorbents regains Nasdaq minimum bid price compliance - Investing.com
Cytosorbents Corporation (CTSO) Stock Price, News, Quote & History - Yahoo! Finance Canada
CytoSorbents Regains Compliance With Nasdaq Minimum Bid Price Requirement - Moomoo
Cytosorbents Corp (CTSO) Q4 2022 Earnings ReportResults, Call & Slides - TipRanks
Cytosorbents Corp (CTSO) Q1 2023 Earnings ReportResults, Call & Slides - TipRanks
Cytosorbents Corp (CTSO) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Cytosorbents Corp (HQE) Q4 2022 Earnings ReportResults, Call & Slides - TipRanks
Cytosorbents Corp (HQE) Q1 2023 Earnings ReportResults, Call & Slides - TipRanks
CEO Phillip Chan Buys 3,774 Shares of CytoSorbents Corp (CTSO) - GuruFocus
Cytosorbents president & COO Vincent Capponi buys $12,536 in stock By Investing.com - Investing.com Australia
Cytosorbents CEO Phillip Chan buys $22,644 in common stock - Investing.com
Cytosorbents (CTSO) CEO adds to stake in open-market buy - Stock Titan
Cytosorbents president & COO Vincent Capponi buys $12,536 in stock - Investing.com
Cytosorbents (CTSO) director buys shares in open-market trades without a preset plan - Stock Titan
Cytosorbents (CTSO) COO adds shares in open‑market buy - Stock Titan
CytoSorbents at H.C. Wainwright conference: breakeven, drug hopes - Investing.com
CytoSorbents Corp (STU:HQE) Stock Price & 30 Year Financial Data - GuruFocus
CytoSorbents to present at H.C. Wainwright conf... - Pluang
CytoSorbents to Present at the H.C. Wainwright 28th Annual Global Investment Conference - PR Newswire
Cytosorbents CEO Phillip Chan buys 200,000 shares for $70,000 By Investing.com - Investing.com South Africa
Cytosorbents CEO Phillip Chan buys 200,000 shares for $70,000 - Investing.com
Cytosorbents Corp (CTSO) CEO bought more shares in the open market, adding to his stake - Stock Titan
CytoSorbents Corp (STU:HQE) Stock Earnings Transcripts - GuruFocus
CytoSorbents to Report Second Quarter 2026 Financial Results and Recent Business Highlights - easternprogress.com
CytoSorbents to present at Moody Capital Soluti... - Pluang
CytoSorbents to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference - The Globe and Mail
CytoSorbents Plans 1-for-20 Reverse Stock Split to Maintain Nasdaq Listing - citybiz
CytoSorbents to implement 1-for-20 reverse stoc... - Pluang
CytoSorbents Announces Reverse Stock Split - Morningstar
CTSO Looks 61.4% Undervalued on GF Value™ Amid Challenging Funda - GuruFocus
CytoSorb reduces severe bleeding by 37% in urge... - pluang.com
CytoSorbents Announces New Real-World Data Demonstrating Significant Reduction in Severe Bleeding Using CytoSorb in CABG Patients on Ticagrelor and Updates Recent DrugSorb-ATR FDA Pre-Submission Meetings - Yahoo Finance
Cytosorbents Earnings Call Balances Progress and Risk - The Globe and Mail
Cytosorbents (CTSO) Chart: Finishes 20.35% Higher at $0.37 for the Current Session; Market Levels: Traders Can Monitor the $0.35-$0.39 Range in the Current UpdateMerger Arbitrage - dars.gov.et
Cytosorbents (CTSO) Shares: Finishes 5.62% Higher at $0.38; Levels: Support at $0.36 and Resistance at $0.40 Frame the Range on the DayDividend Stock Picks - careplusvn.com
Cytosorbents (CTSO) Financial Update: EPS Comes in Below Forecast; Market Follow-Through: Shares Finish 4.56% LowerEarnings Season Outlook - vinanet.vn
CTSO: CytoSorbents Future Value Drivers Support Price Target of $4.00 - Yahoo Finance
CytoSorbents (CTSO) wins approval for reverse split and director slate at 2026 meeting - Stock Titan
Cytosorbents (CTSO) Q2 2026 Earnings Call Transcript - The Globe and Mail
Cytosorbents Corp. R (HQE1.DU) Q1 FY2026 earnings call transcript - Yahoo Finance
Cytosorbents Corp (CTSO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Q2 2026 Cytosorbents Corp Earnings Call Transcript - GuruFocus
Cytosorbents Corp (CTSO) Stock News Today - TradingKey
CytoSorbents posts $9.6M Q2 revenue, narrows cash burn and advances DrugSorb-ATR regulatory path - TradingView
Cytosorbents Corporation Q2 2026 Earnings Call Summary - Yahoo Finance
CytoSorbents Corp (CTSO) (Q2 2026) Earnings Call Highlights: Nea - GuruFocus
Is CytoSorbents Corp (CTSO) a Value Opportunity After Q2 Earning - GuruFocus
CytoSorbents Corp (CTSO) (Q2 2026) Earnings Call Highlights: Nearing Breakeven with Strong ... - finance.yahoo.com
Finanzdaten der Cytosorbents Corp-Aktie (CTSO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cytosorbents Corp-Aktie (CTSO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Capponi Vincent | President and COO |
Sep 14 '26 |
Buy |
6.05 |
2,073 |
12,537 |
40,387 |
| Sobel Alan D. | Director |
Sep 15 '26 |
Buy |
6.10 |
2,500 |
15,254 |
9,887 |
| Chan Phillip P. | Chief Executive Officer |
Sep 04 '26 |
Buy |
0.35 |
200,000 |
70,000 |
1,944,432 |
| MARIANI PETER J | Chief Financial Officer |
Jun 15 '26 |
Buy |
0.44 |
100,000 |
44,000 |
638,113 |
| Chan Phillip P. | Chief Executive Officer |
Jun 12 '26 |
Buy |
0.40 |
251,136 |
100,454 |
1,734,099 |
| Chan Phillip P. | Chief Executive Officer |
Jun 15 '26 |
Buy |
0.43 |
10,333 |
4,443 |
1,744,432 |
2.75%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):